Scholar Rock is trading $49.09, up +5.22%, as broader risk appetite supports equities.

  • The move reflects an opening-week recovery in a broadly stronger market; the S&P 500 is up 1.01% and Nasdaq is up 1.59%.
  • It follows recent post-approval profit-taking after FDA approval of ISEMBYLD and mixed analyst reactions, including Barclays’ downgrade.
  • No new company-specific catalyst was identified for September 21, 2026.